[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-device-PZM":3},{"classification":4,"mappedDevices":42,"similarCandidates":43,"relatedClassifications":124,"syncDates":125,"translation":132,"marketSummary":139,"recalls":153,"k510s":155,"pmas":194},{"id":5,"product_code":6,"device_name":7,"device_class":8,"regulation_number":9,"medical_specialty":10,"medical_specialty_description":11,"review_panel":10,"submission_type_id":12,"definition":13,"implant_flag":14,"life_sustain_support_flag":14,"gmp_exempt_flag":14,"raw":15,"created_at":37,"updated_at":38,"recall_count":39,"latest_recall_date":40,"k510_count":41,"pma_count":39,"event_count":39},5407,"PZM","Next Generation Sequencing Based Tumor Profiling Test","2","866.6080","PA","Pathology","1","A next-generation sequencing based tumor profiling test is a qualitative in vitro diagnostic test intended to detect mutations in a broad panel of targeted genes that are somatically altered in malignant neoplasms from tumor specimens obtained from patients diagnosed with malignant solid neoplasms using targeted next-generation sequencing.",false,{"openfda":16,"definition":13,"device_name":7,"review_code":27,"device_class":8,"implant_flag":34,"product_code":6,"review_panel":10,"gmp_exempt_flag":34,"third_party_flag":35,"medical_specialty":10,"regulation_number":9,"submission_type_id":12,"unclassified_reason":27,"life_sustain_support_flag":34,"medical_specialty_description":11,"summary_malfunction_reporting":36},{"k_number":17,"fei_number":26,"registration_number":33},[18,19,20,21,22,23,24,25],"K250003","K202304","DEN170058","K192063","K241868","K190661","K210017","K260235",[27,28,29,30,31,32],"","3011805506","3043140667","3013200421","3003335080","3043050156",[27,28,29,30,31,32],"N","Y","Ineligible","2026-08-18T05:52:52.566809+00:00","2026-08-24T02:00:48.366308+00:00",0,null,8,[],[44,53,60,68,76,84,92,100,108,116],{"medical_device_id":45,"generic_name":46,"class_classification":47,"jmdn_code":48,"name_similarity":49,"definition_similarity":50,"vector_similarity":51,"score":52},1147,"遺伝子変異解析セット（がんゲノムプロファイリング検査用）","Ⅲ","60943013",0.197674,0.229965,0.746032,0.0322665,{"medical_device_id":54,"generic_name":55,"class_classification":47,"jmdn_code":56,"name_similarity":57,"definition_similarity":58,"vector_similarity":59,"score":52},1157,"遺伝子変異解析システム（がんゲノムプロファイリング検査用）","60943033",0.177778,0.252336,0.768227,{"medical_device_id":61,"generic_name":62,"class_classification":47,"jmdn_code":63,"name_similarity":64,"definition_similarity":65,"vector_similarity":66,"score":67},1151,"遺伝子変異解析プログラム（がんゲノムプロファイリング検査用）","60943023",0.173913,0.239344,0.753691,0.0312805,{"medical_device_id":69,"generic_name":70,"class_classification":47,"jmdn_code":71,"name_similarity":72,"definition_similarity":73,"vector_similarity":74,"score":75},1184,"腫瘍悪性度判定支援プログラム","61231003",0.148936,0.241158,0.659621,0.0277459,{"medical_device_id":77,"generic_name":78,"class_classification":47,"jmdn_code":79,"name_similarity":80,"definition_similarity":81,"vector_similarity":82,"score":83},972,"高周波病変ジェネレータ","35156000",0.2,0.209945,0.540179,0.016129,{"medical_device_id":85,"generic_name":86,"class_classification":47,"jmdn_code":87,"name_similarity":88,"definition_similarity":89,"vector_similarity":90,"score":91},1140,"体細胞遺伝子変異解析システム（抗悪性腫瘍薬適応判定用）","71059003",0.0873016,0.282738,0.699237,0.015625,{"medical_device_id":93,"generic_name":94,"class_classification":95,"jmdn_code":96,"name_similarity":97,"definition_similarity":98,"vector_similarity":99,"score":91},2385,"血漿分離用血液回路","Ⅱ","70546000",0.188406,0.174917,0.44992,{"medical_device_id":101,"generic_name":102,"class_classification":47,"jmdn_code":103,"name_similarity":104,"definition_similarity":105,"vector_similarity":106,"score":107},1165,"体細胞遺伝子変異解析セット（抗悪性腫瘍薬適応判定用）","71059023",0.0983607,0.2589,0.68824,0.0153846,{"medical_device_id":109,"generic_name":110,"class_classification":111,"jmdn_code":112,"name_similarity":113,"definition_similarity":114,"vector_similarity":115,"score":107},3876,"汎用電動式手術台","Ⅰ","36867020",0.186667,0.176667,0.487245,{"medical_device_id":117,"generic_name":118,"class_classification":47,"jmdn_code":119,"name_similarity":120,"definition_similarity":121,"vector_similarity":122,"score":123},1153,"体細胞遺伝子変異解析プログラム（抗悪性腫瘍薬適応判定用）","70159013",0.0866142,0.278846,0.679138,0.0151515,[],{"510k":126,"classification":127,"enforcement":128,"event":129,"pma":130,"warning_letter":131},"2026-08-24T02:00:50.297+00:00","2026-08-24T02:00:49.319+00:00","2026-08-24T02:00:50.059+00:00","2026-08-24T04:00:49.186+00:00","2026-08-24T02:00:50.609+00:00","2026-08-20T03:28:02.95+00:00",{"product_code":6,"device_name_ja":133,"definition_ja":134,"commentary_ja":135,"model_name":136,"source_hash":137,"reviewed_by":40,"reviewed_at":40,"created_at":138,"updated_at":138},"次世代シーケンシングによる腫瘍プロファイリング検査","次世代シーケンシングによる腫瘍プロファイリング検査とは、悪性固形腫瘍と診断された患者から採取された腫瘍検体を用いて、標的化された次世代シーケンシングにより、悪性腫瘍において体細胞的に変化した幅広い標的遺伝子パネルにおける変異を検出することを目的とした、定性的な体外診断検査である。","米国では本品目はクラスIIに分類されており、市販前届出（510(k)）の対象となっています。510(k)は、既存の同等な医療機器との実質的同等性を示すことにより市販が認められる審査区分であり、市販前承認（PMA）に比べて簡略化された手続きとなっています。この区分は、中程度のリスクを有すると判断される医療機器に適用されるものです。","claude-sonnet-5","ee9ec76cb1cd774416ebf7ea67dc36103a5013d7d6f086eb057ff64880271fea","2026-08-24T02:35:22.423427+00:00",{"product_code":6,"summary_ja":140,"stats":141,"stats_hash":151,"model_name":136,"created_at":152,"updated_at":152},"510(k)の累計件数は8件で、8社が申請しており、直近5年間では4件の判定が行われています。最新の判定は2026年5月です。不具合報告および回収については、いずれも累計件数が0件で、報告や実施の実績は確認されていません。",{"pma":142,"k510":143,"as_of":146,"events":147,"recalls":148,"top_problems":150},{"latest":40,"originals":39,"supplements":39},{"total":41,"last5y":144,"latest":145,"applicants":41},4,"2026-05-12","2026-08",{"death":39,"other":39,"total":39,"injury":39,"last5y":39,"malfunction":39,"latest_month":40},{"total":39,"last5y":39,"latest":40,"class_i":39,"class_ii":39,"class_iii":39,"top_root_causes":149},[],[],"5648cc12552183900fc7ccc72bff91bf05f05685f28c1b9a27f22e8c03da6158","2026-08-24T05:15:00.389328+00:00",{"items":154,"total":39},[],{"items":156,"total":41},[157,163,167,171,175,180,184,188],{"k_number":25,"device_name":158,"applicant":159,"decision_date":145,"clearance_type":160,"decision_code":161,"statement_or_summary":162},"CellDx-Tissue","Datar Cancer Genetics Private Limited","Traditional","SESE","Summary",{"k_number":22,"device_name":164,"applicant":165,"decision_date":166,"clearance_type":160,"decision_code":161,"statement_or_summary":162},"xR IVD","Tempus AI, Inc.","2025-09-19",{"k_number":18,"device_name":168,"applicant":169,"decision_date":170,"clearance_type":160,"decision_code":161,"statement_or_summary":162},"GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS6005)","Geneseeq Technology, Inc.","2025-08-29",{"k_number":24,"device_name":172,"applicant":173,"decision_date":174,"clearance_type":160,"decision_code":161,"statement_or_summary":162},"ACTOnco, ACTOnco IVD","Act Genomics","2022-12-23",{"k_number":19,"device_name":176,"applicant":177,"decision_date":178,"clearance_type":160,"decision_code":161,"statement_or_summary":179},"NYU Langone Genome PACT (Genome Profiling of Actionable Cancer Targets)","Nyu Langone Medical Center","2021-07-14","Statement",{"k_number":21,"device_name":181,"applicant":182,"decision_date":183,"clearance_type":160,"decision_code":161,"statement_or_summary":162},"PGDx elio tissue complete","Personal Genome Diagnostics","2020-04-24",{"k_number":23,"device_name":185,"applicant":186,"decision_date":187,"clearance_type":160,"decision_code":161,"statement_or_summary":162},"Omics Core","Nanthealth, Inc.","2019-11-09",{"k_number":20,"device_name":189,"applicant":190,"decision_date":191,"clearance_type":192,"decision_code":193,"statement_or_summary":40},"MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay","Memorial Sloan-Kettering Cancer Center","2017-11-15","Direct","DENG",{"items":195,"total":39},[]]